PTO/SB/08a(04-07)
Approved for use through 7/31/2006 OMB 0651-0031
US Patent & Tradement Office, U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO INFORMATION DISCLOSURE Complete if Known STATEMENT BY APPLICANT **Application Number** 10/509,009 May 3, 2005 **Filing Date** Chiquet-Ehrismann et al. **First Named Inventor** 1643 **Art Unit Examiner Name** Anne Gussow (Use as many sheets as necessary) Attorney Docket No: FM-05-US Sheet of

	US PATENT DOCUMENTS								
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate				

FOREIGN PATENT DOCUMENTS								
Examiner thitials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T²			

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		REARDON, DAVID A. et al., Phase II Trial of Murine ¹³¹ I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas; Journal of Clinical Oncology, Vol 20; No 5; pp 1389-1397; March 1, 2002.	